Literature DB >> 2995470

A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis.

M R Costanzo-Nordin, E A Reap, J B O'Connell, J A Robinson, P J Scanlon.   

Abstract

Nonsteroid anti-inflammatory drugs are often used to treat myalgias and arthralgias in enteroviral infections, but their effects on acute viral myocarditis are unknown. The effect of the nonsteroidal anti-inflammatory drug, ibuprofen, on acute viral myocarditis was studied in 75 four week old male BALB/c mice infected with 1.75 X 10(7) plaque-forming units of Coxsackie virus B3 on day 0. Ibuprofen was given intraperitoneally at a dose of 15 mg/kg body weight daily. The mice were assigned to four groups--Group I, 18 uninfected mice given ibuprofen on days 1 to 14; Group II, 18 infected, untreated mice; Group III, 20 infected mice given ibuprofen on days 1 to 14; and Group IV, 17 infected mice given ibuprofen on days 7 to 14. Nine animals in Group I, eight in Group II and seven in Group III were killed on day 7; the remaining mice were killed on day 14. Heart viral cultures and histologic analysis were done. Cultures at days 7 and 14 were all negative. Inflammation and necrosis analyzed in each animal were graded 0 to 4, with grade 4 representing widespread inflammation and necrosis. The heart was histologically normal in all 18 uninfected mice (Group I) given ibuprofen only. Inflammation and necrosis were not significantly different in Group II (infected, untreated) and Group III (infected, treated beginning day 1) mice killed at day 7. Inflammation scores of mice killed on day 14 were 2.1 +/- 0.6 (Group II), 3.1 +/- 0.7 (Group III) and 2.9 +/- 1.0 (Group IV infected, treated days 7 to 14).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995470     DOI: 10.1016/s0735-1097(85)80312-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

Review 1.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

Review 2.  Coxsackievirus infection as a trigger of cardiac autoimmunity.

Authors:  L J Wolfgram; N R Rose
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 3.  Myocarditis.

Authors:  Sandeep Sagar; Peter P Liu; Leslie T Cooper
Journal:  Lancet       Date:  2011-12-18       Impact factor: 79.321

Review 4.  Recognition and optimum management of myocarditis.

Authors:  A L Caforio; W J McKenna
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 5.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 6.  Viral myocarditis--diagnosis, treatment options, and current controversies.

Authors:  Ari Pollack; Amy R Kontorovich; Valentin Fuster; G William Dec
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 7.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

8.  Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.

Authors:  J R Gebhard; C M Perry; S Harkins; T Lane; I Mena; V C Asensio; I L Campbell; J L Whitton
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

9.  Verapamil ameliorates the clinical and pathological course of murine myocarditis.

Authors:  R Dong; P Liu; L Wee; J Butany; M J Sole
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 10.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.